![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Amryt Pharma Plc | LSE:AMYT | London | Ordinary Share | GB00BKLTQ412 | ORD 6P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 143.00 | 151.00 | 170.00 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
16/3/2021 05:22 | This will hit £10 in the years to come. Wise investment. | ![]() bugsbunny10 | |
15/3/2021 16:26 | I thought you were referring to original AMYT holders, thecynical1. Sorry about the confusion. I can't remember at what price FAST floated at. Was it back in 2011? It did rise to circa 30p fairly soon after floating. I originally bought into FAST back in early 2015 when it was effectively a cash shell and the share price was just over 2p. | ![]() papillon | |
15/3/2021 16:03 | Papillon.....I was referring to the original FAST holders......㊋ | thecynical1 | |
15/3/2021 11:52 | Sudocreme King Stafford to the rescue Today 11:23 Must be real positive on Filsuvez and Stafford knows his ointments. Where are the multi millionaires in the USA and all their friends and why aren't they getting involved. >>>>> The above was posted by Bronxville, just now, on the lse AMYT bb. Bronxville is a very knowledgeable Irish investor. What Bronxville states is very true. Irish, Ray Stafford, the "Sudocreme King", really does know his ointments and his 300k buy is a real vote of confidence in Filsuvez. | ![]() papillon | |
15/3/2021 11:42 | Especially for a chairman, Moorsie2, with Ray Stafford's exemplary business track record. Be interesting to see how this news is received on Nasdaq. | ![]() papillon | |
15/3/2021 11:41 | Especially for a chairman, Moorsie2, with Ray Stafford's exemplary business track record. | ![]() papillon | |
15/3/2021 11:23 | 600k stg of personal money in a business this size is a very strong validation from the Chairman | ![]() moorsie2 | |
15/3/2021 10:38 | Beaten to the punch by post above but will leave with the link in! Decent looking slug from the Chairman... | ![]() cwa1 | |
15/3/2021 10:37 | Bronxville on the lse bb noted a 300k buy @ a price of £2 per share reported late Friday. Today's RNS records that our chairman, Ray Stafford, bought those shares!! He's no mug!! The last time he bought AMYT shares the AMYT share price went from circa £1 to £1.50 in a short space of time. PS If he thinks AMYT shares are cheap, then they must be!! | ![]() papillon | |
12/3/2021 16:21 | Happy to be patient though. They appear to be very ambitious and achieve what they set themselves to do. Hopefully the share price will recognise the progress at sometime! | ![]() bazworth | |
12/3/2021 15:53 | Read my post again, thecynical1. Those who took part in the original placing in AMYT, when it listed after the RTO into FAST, are NOT down a small fortune!! Where do you get that idea from?? Those who took part in the original placing for AMYT at 24p in 2016 are currently in PROFIT! Why? Because there has been a 1 for 6 placing since then which equates that original placing price to 144p. At the current AMYT share price of 198p that's a 54p PROFIT and not a loss! Read my post again and using some basic arithmetic you should understand. PS the 1 for 8 consolidation was completed before AMYT listed. It basically converted the number of FAST shares into new AMYT shares. | ![]() papillon | |
12/3/2021 15:36 | Well, bazworth, big volume on Nasdaq so far today. Unfortunately the price of the ADS's is weaker, so far today. | ![]() papillon | |
12/3/2021 11:09 | Best not to think about it!! | ![]() bazworth | |
12/3/2021 11:00 | Papillon - thanks. So all of the original holders are down a small fortune.....🙄 | thecynical1 | |
12/3/2021 10:55 | And we are all Saints by now ! ;) | ![]() richpassi | |
12/3/2021 10:51 | This is a patience play.... | ![]() moorsie2 | |
12/3/2021 07:03 | The results haven’t quite had the effect I was hoping for! | ![]() bazworth | |
08/3/2021 21:25 | Looks like Joe & Rory have every reason to let the share-price fly!! Sincerely hope they make an absolute killing!! | ![]() bazworth | |
08/3/2021 12:32 | onceaday gene therapies aim is to cure, but most therapies only treat diseases.. that's including Krystal's. It heals the wound but does not cure the disease. The therapy is there if and when the skin is again wounded. The way you cure via gene therapy is via a vaccine. Krystal's product is topical, not a vaccine. | ![]() delta0091 | |
08/3/2021 12:14 | It's crazy!! AMYT is consistently delivering on or ahead of expectations and there is no response positive whatsoever!! Reckon there is far more in the pipeline here!! It will happen eventually, I hope!! Cheers | ![]() bazworth | |
08/3/2021 12:11 | As expected Good News and down it goes ! | ![]() richpassi | |
08/3/2021 07:20 | And another brick in the wall...... | ![]() bazworth | |
08/3/2021 06:21 | Delta B-VEC is a gene therapy that restores missing collagen to the cells. The advantage is that it restores the skin elasticity greatly improving robustness. Amryt's AP103 potentially has a similar method of action to Krystal's B-VEC but that has yet to be developed. | ![]() onceaday | |
08/3/2021 00:12 | Whatno I believe Krystal's treatment heals rather than cure... Like amryts product | ![]() delta0091 | |
06/3/2021 16:41 | thecynical1, there have been 2 consolidations since the FAST days. A 1 for 8 consolidation back in 2016 when AMYT RTO'd into FAST. AMYT had a placing at 24p when it listed (equivalent to 3p pre consolidation). Then there was a 1 for 6 consolidation following the deal with Novelion for Aegerion back in 2019. At today's price that equates to 4.27p per old FAST share price pre consolidations (205 ÷ 8 ÷ 6). Not a great share price performance over the years. | ![]() papillon |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions